 | |
| Clinical data | |
|---|---|
| Routes of administration | Topical (ointment,eye drops) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.217.969 |
| Chemical and physical data | |
| Formula | C25H26F4N2O2 |
| Molar mass | 462.489 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Mapracorat (INN, code namesBOL-303242-X,ZK-245186[1]) is ananti-inflammatory drug belonging to the experimental class ofselective glucocorticoid receptor agonists (SEGRAs). It is inclinical trials for the topical treatment ofatopic dermatitis,[2] inflammation followingcataract surgery,[3] andallergic conjunctivitis.[4] Preliminary investigation for the treatment ofkeratoconjunctivitis sicca has been conducted in cellular models.[1]
Phase II clinical trials with mapracorat started in summer 2009. One trial was adouble blind dose finding study for anointment against atopic dermatitis. It tested concentrations of 0.01%, 0.03% and 0.1% versusplacebo over four weeks in around 64 patients. This trial was conducted by Intendis, a part ofBayer HealthCare Pharmaceuticals specialized ondermatology, and completed in September or October 2010.[2] The other trial, also with a double blind design, evaluated anophthalmicsuspension for the treatment of inflammation following cataract surgery. Various concentrations and dosing schemes were tested versus placebo in about 550 patients. The study was conducted byBausch & Lomb and completed in September 2010.[3] Its successor study, a phase III trial, started in November 2010 and completed in August 2011.[5]
As of January 2017[update] no study results are available.
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
 | Thisdermatologicdrug article is astub. You can help Wikipedia byexpanding it. |